Sugi Predict

Sugi Predict / Compounds / SCHEMBL14717889

SCHEMBL14717889

SCHEMBL14717889

CC(C)S(=O)(=O)c1ccc2nccc(Nc3cc4[nH]ncc4cc3C#N)c2c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 11/20 0.51
▸ RIPK1 Q13546 2/20 0.48
▸ RIPK3 Q9Y572 2/20 0.47
▸ RAF1 P04049 7/20 0.47
▸ BRAF P15056 7/20 0.47
▸ KCNH2 Q12809 6/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MAPK14 Q16539 2/20 0.39
▸ RET P07949 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ PKMYT1 Q99640 1/20 0.39
▸ GAK O14976 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ TGFBR1 P36897 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12180825 0.83 RIPK2 (0.51) RIPK2RIPK1RIPK3RAF1BRAF
SCHEMBL12180826 0.83 RAF1 (0.44) RAF1BRAFMKNK1
SCHEMBL2595045 0.82 RIPK1 (0.62) RIPK2RIPK1RIPK3RAF1BRAF
SCHEMBL17044083 0.82 RAF1 (0.37) RIPK2RAF1BRAFMKNK1
SCHEMBL2589426 0.77 RIPK2 (0.52) RIPK2RIPK1RIPK3RAF1BRAF
SCHEMBL2594916 0.71 RIPK2 (0.49) RIPK2RIPK1RIPK3RAF1BRAF
SCHEMBL2589414 0.71 RIPK2 (0.65) RIPK2RIPK1RIPK3RAF1BRAF
SCHEMBL2595976 0.70 RIPK2 (0.77) RIPK2RIPK1RIPK3RAF1BRAF
SCHEMBL600919 0.70 RIPK2 (0.74) RIPK2RIPK1RIPK3KCNH2MAPK14
SCHEMBL2589201 0.69 RIPK2 (0.52) RIPK2RIPK1RIPK3RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 — — EP claimed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 — — US claimed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 — — US disclosed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 — — US disclosed
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-03 — — US disclosed
EP-2566477-B1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-02 — — EP disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 — — US disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 — — US disclosed
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060222-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885RIPK1 410/4885RIPK3 421/4885
US-20130053375-A1 AMINO-QUINOLINES AS KINASE INHIBITORS ABL1, MAP3K2, MAP4K2 RIPK2 326/4885RIPK1 410/4885RIPK3 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.